Mi SciELO
Servicios Personalizados
Articulo
Indicadores
Citado por SciELO
Links relacionados
Similares en SciELO
Compartir
Revista Cubana de Endocrinología
versión On-line ISSN 1561-2953
Resumen
MONTEAGUDO PENA, Gilda; HERNANDEZ ROMERO, Maidelys; GOMEZ ALZUGARAY, Manuel y OVIES CARBALLO, Gisel. Late-Onset Hypogonadism Treatment with Testosterone. Rev Cubana Endocrinol [online]. 2020, vol.31, n.2 Epub 06-Nov-2020. ISSN 1561-2953.
Introduction:
The use of testosterone replacement therapy in older men has increased in recent years, which has generated multiple controversies not yet resolved about its benefits and potential risks, especially those related to the development or worsening of the prostate or cardiovascular disease.
Methods:
A literature review was conducted with the aim of offering a state of the art that helps clinicians make decisions when considering testosterone treatment in patients with late-onset hypogonadism. The information search was carried out with the Google Scholar, Medline and Pubmed search engines.
Conclusions:
Testosterone treatment in late-onset hypogonadism is safe, rational, and evidence-based, but it is not recommended to offer it to all older men with low serum testosterone levels. It is advised in those with overt symptoms of androgen deficiency, without active prostate, breast or liver cancer, elevated hematocrit, benign prostatic hyperplasia with severe obstructive symptoms, untested prostate nodule or induration, prostate specific antigen> 4 ng / mL (or > 3 ng / mL in high-risk patients), severe untreated obstructive sleep apnea, short-term fertility wishes, uncontrolled heart failure, acute myocardial infarction or stroke in the last SIX months, or thrombophilia. It is recommended to carry out quarterly monitoring during the first year and then according to each case, which includes evaluation of the clinical response, of conditions that can be aggravated by treatment, and of laboratory parameters.
Palabras clave : late-onset hypogonadism; testosterone replacement therapy; testosterone and prostate; testosterone and cardiovascular disease.